The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: PET Acetate for Castrate-Resistant Prostate Cancer on Chemotherapy
Official Title: PET Acetate for Docetaxel Response Assessment in Hormone-Refractory Prostate Cancer
Study ID: NCT01144897
Brief Summary: One purpose of this research study is to examine if a special type of imaging test, a positron emission tomography (PET) scan using the radioactive material \[C-11\] acetate, will be helpful in detecting prostate cancer lesions in subjects with castrate-resistant prostate cancer (CRPC). This PET scan will be combined with a computed tomography (CT) scan taken during the same imaging session. The other purpose of the PET-CT scan using \[C-11\] acetate (PET Acetate Scan) is to assist in identifying who is responding to the treatment (docetaxel chemotherapy).
Detailed Description: The purpose of the current pilot clinical trial is to attempt to identify the safety and accuracy of PET-acetate imaging in the assessment of response of persons undergoing first-line docetaxel for CRPC. If successful, the current research could lead to the incorporation of PET-acetate into future study protocols where continuation of chemotherapy is based on early PET-acetate results, provided that effective second-line therapy options are available (which is an expectation for the near future, based on several ongoing and presented phase III trials).
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Name: Daniel Vaena, MD
Affiliation: University of Iowa
Role: PRINCIPAL_INVESTIGATOR